Related Experiment Video
Updated: Sep 20, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Coronary intervention with a heparin-coated stent and aspirin only
Peter N Ruygrok1, Kui-Hian Sim, Charles Chan
1Cardiology Department, Green Lane Hospital, Green Lane West, Auckland 1003, New Zealand. PRuygrok@adhb.govt.nz
Insights
Aspirin monotherapy after heparin-coated stent implantation is safe and feasible for preventing major adverse cardiovascular events. Further randomized trials are recommended to confirm these findings in a larger patient cohort.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Heparin-coated stents aim to reduce thrombotic events post-percutaneous coronary intervention.
- Standard antiplatelet regimens often include dual antiplatelet therapy (ticlopidine or clopidogrel) in addition to aspirin.
- The necessity of dual therapy with newer stent technologies requires ongoing investigation.
Purpose of the Study:
- To evaluate the safety and efficacy of aspirin monotherapy as an antiplatelet regimen.
- To assess outcomes following successful heparin-coated stent implantation.
- To determine if aspirin alone is sufficient post-procedure.
Main Methods:
- Prospective, non-randomized, multi-center pilot study.
- 122 patients undergoing percutaneous coronary intervention with heparin-coated stents.
- Treatment with aspirin only, with one-month clinical follow-up.
Main Results:
- No major adverse cardiovascular events, including subacute stent thrombosis, observed in 122 patients.
- Mean patient age 57.2 years; 79% male; 31% with unstable angina.
- 5 patients readmitted for non-procedural reasons.
Conclusions:
- Aspirin monotherapy with heparin-coated stents appears safe and feasible.
- The findings support the potential for simplified antiplatelet regimens.
- A larger, randomized trial is warranted to confirm efficacy.
Objectives:
To determine the safety and efficacy of a post-stenting anti-platelet regimen of aspirin without additional ticlopidine or clopidogrel after successful heparin-coated stent implantation.
Methods:
A prospective, non-randomized, multi-center pilot study of patients undergoing percutaneous coronary intervention, including those with acute coronary syndromes and small vessels with one-month clinical follow-up, was undertaken. Patients received a heparin-coated stent and were treated with aspirin only.
Results:
Over a period of 6 months, a total of 122 patients were recruited in 6 centers. Their mean age was 57.2 10.0 years, 79% were male and 31% had unstable angina. Most (75%) had single-vessel disease, predominantly of the left anterior descending artery (51%), with a mean reference diameter of 2.44 mm 0.44 mm at baseline and 2.48 0.41 mm post stenting. At a 1-month clinical follow-up, no major adverse cardiovascular events (including subacute stent thrombosis) had occurred. Five patients were readmitted to hospital for symptoms unrelated to the interventional procedure.
Conclusions:
Heparin-coated stent implantation using an antiplatelet regimen of aspirin only, appears to be safe and feasible. A randomized trial of a larger number of patients appears warranted.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Angina IV: Management